These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 6339689)

  • 41. Tumor targeting with newly designed biparatopic antibodies directed against two different epitopes of the carcinoembryonic antigen (CEA).
    Robert B; Dorvillius M; Buchegger F; Garambois V; Mani JC; Pugnières M; Mach JP; Pèlegrin A
    Int J Cancer; 1999 Apr; 81(2):285-91. PubMed ID: 10188732
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative localization of murine monoclonal antibody Me1-14 F(ab')2 fragment and whole IgG2a in human glioma xenografts.
    Colapinto EV; Humphrey PA; Zalutsky MR; Groothuis DR; Friedman HS; de Tribolet N; Carrel S; Bigner DD
    Cancer Res; 1988 Oct; 48(20):5701-7. PubMed ID: 3167830
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody.
    Marshall D; Pedley RB; Melton RG; Boden JA; Boden R; Begent RH
    Br J Cancer; 1995 Jan; 71(1):18-24. PubMed ID: 7529526
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhancement of colorectal tumor targeting using a novel biparatopic monoclonal antibody against carcinoembryonic antigen in experimental radioimmunoguided surgery.
    Kim JC; Roh SA; Koo KH; Ryu JH; Hong HK; Oh SJ; Ryu JS; Kim HJ; Bodmer WF
    Int J Cancer; 2002 Feb; 97(4):542-7. PubMed ID: 11802220
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Numerical selection of optimal tumor imaging agents with application to engineered antibodies.
    Williams LE; Wu AM; Yazaki PJ; Liu A; Raubitschek AA; Shively JE; Wong JY
    Cancer Biother Radiopharm; 2001 Feb; 16(1):25-35. PubMed ID: 11279795
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Improved tumor detection by anti-CEA chimeric Fab oligomers with disulfide linkages in a pancreatic-carcinoma-xenograft model.
    Kamigaki T; Yamamoto M; Ohyanagi H; Ohya M; Kono A; Ohtani W; Narita Y; Ohkubo M; Ohmura T; Saitoh Y
    Int J Cancer; 1996 Apr; 66(2):261-7. PubMed ID: 8603822
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biodistribution of monoclonal IgG1, F(ab')2, and Fab' in mice after intravenous injection. Comparison between anti-B cell (anti-Lyb8.2) and irrelevant (MOPC-21) antibodies.
    Holton OD; Black CD; Parker RJ; Covell DG; Barbet J; Sieber SM; Talley MJ; Weinstein JN
    J Immunol; 1987 Nov; 139(9):3041-9. PubMed ID: 3499463
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Iodine-131-labeled MAb F(ab')2 fragments are more efficient and less toxic than intact anti-CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice.
    Buchegger F; Pèlegrin A; Delaloye B; Bischof-Delaloye A; Mach JP
    J Nucl Med; 1990 Jun; 31(6):1035-44. PubMed ID: 2348233
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Radiolocalization of human pancreatic tumors in athymic mice by monoclonal antibody DU-PAN 1.
    Worlock AJ; Zalutsky MR; Metzgar RS
    Cancer Res; 1990 Nov; 50(22):7246-51. PubMed ID: 2224857
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics of 99mTc-metallothionein-B72.3 and its F(ab')2 fragment.
    Brown BA; Dearborn CB; Drozynski CA; Sands H
    Cancer Res; 1990 Feb; 50(3 Suppl):835s-839s. PubMed ID: 2297730
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Enhanced delivery of a monoclonal antibody F(ab')2 fragment to subcutaneous human glioma xenografts using local hyperthermia.
    Cope DA; Dewhirst MW; Friedman HS; Bigner DD; Zalutsky MR
    Cancer Res; 1990 Mar; 50(6):1803-9. PubMed ID: 2407344
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
    Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
    MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preparation of F(ab')2 fragments from monoclonal mouse IgG1 suitable for use in radioimaging.
    Kurkela R; Vuolas L; Vihko P
    J Immunol Methods; 1988 Jun; 110(2):229-36. PubMed ID: 3132507
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunoscintigraphy of gastric or colon carcinoma with F(ab')2 fragments of anti-CEA monoclonal antibody.
    Amendolagine F; Allegra V; Tenti M; Lobrano V; Pannozzo G
    Rays; 1987; 12(1):67-71. PubMed ID: 3628863
    [No Abstract]   [Full Text] [Related]  

  • 55. Phase-I/II radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab')2 in patients with non-resectable liver metastases from colorectal cancer.
    Ychou M; Pelegrin A; Faurous P; Robert B; Saccavini JC; Guerreau D; Rossi JF; Fabbro M; Buchegger F; Mach JP; Artus JC
    Int J Cancer; 1998 Feb; 75(4):615-9. PubMed ID: 9466665
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Improved radioimmunoimaging of human tumor xenografts by a mixture of monoclonal antibody F(ab')2 fragments.
    Munz DL; Alavi A; Koprowski H; Herlyn D
    J Nucl Med; 1986 Nov; 27(11):1739-45. PubMed ID: 3772507
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of a direct method for technetium labeling intact and F(ab')2 1A3, an anticolorectal monoclonal antibody.
    Schwarz SW; Connett JM; Anderson CJ; Rocque PA; Philpott GW; Guo LW; Welch MJ
    Nucl Med Biol; 1994 May; 21(4):619-26. PubMed ID: 9234319
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model.
    Pedley RB; Boden JA; Boden R; Dale R; Begent RH
    Br J Cancer; 1993 Jul; 68(1):69-73. PubMed ID: 8318423
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Kinetics and tissue distribution of the radiolabeled chimeric monoclonal antibody MOv18 IgG and F(ab')2 fragments in ovarian carcinoma patients.
    Buist MR; Kenemans P; den Hollander W; Vermorken JB; Molthoff CJ; Burger CW; Helmerhorst TJ; Baak JP; Roos JC
    Cancer Res; 1993 Nov; 53(22):5413-8. PubMed ID: 8221680
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.
    Casey JL; King DJ; Chaplin LC; Haines AM; Pedley RB; Mountain A; Yarranton GT; Begent RH
    Br J Cancer; 1996 Nov; 74(9):1397-405. PubMed ID: 8912535
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.